China Diagnostics Business Solid For Roche
This article was originally published in PharmAsia News
The Asia-Pacific region and other emerging markets performed well for Roche last year, with the Diagnostics division in particular benefiting from solid growth in China.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.